Ep. 119: Phase 2 HOPE clinical trial results
Moderator: Theodoros M. Mavridis (Dublin, Ireland) Guest: Messoud Ashina (Glostrup, Denmark) In this episode Theodoros M. Mavridis and Messoud Ashina delve into the findings of the Phase 2 HOPE clinical trial, which assesses the efficacy and safety of Lu
Audio is streamed directly from the publisher (audio.podigee-cdn.net) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Moderator: Theodoros M. Mavridis (Dublin, Ireland)
Guest: Messoud Ashina (Glostrup, Denmark)
In this episode Theodoros M. Mavridis and Messoud Ashina delve into the findings of the Phase 2 HOPE clinical trial, which assesses the efficacy and safety of Lu AG09222, a monoclonal antibody that targets the PACAP pathway. They explore the potential of this innovative treatment for migraine prevention while highlighting the critical role of the PACAP pathway in migraine pathophysiology.